Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 1.319
Filtrar
1.
J Pediatr Orthop ; 42(7): 387-392, 2022 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-35749762

RESUMEN

PURPOSE: The burden of upper extremity (UE) osteochondromas on function and self-perception among pediatric patients is unclear. The purpose of our study was to study the impact of osteochondromas in comparison to population norms and to evaluate solitary versus multiple osteochondromas on subjective UE function as measured by patient rated outcomes. METHODS: We utilized the CoULD (Congenital Upper Limb Differences) Registry to review all pediatric patients presenting with osteochondromas between January 2014 and February 2021. Demographic information was collected and patients were classified as having either single or multiple osteochondromas. Patient-Reported Outcome Measurement Information System (PROMIS) and Pediatric Outcomes Data Collection Instrument (PODCI) tools were utilized for assessment. Scores for PODCI subscales of UE function, Pain/comfort, and Happiness and PROMIS domains of UE Function, Pain, Depression, Anxiety, and Peer Relations were reviewed. Differences between groups were analyzed using the Student t test. RESULTS: Ninety-nine patients met inclusion criteria for the study with an average age of presentation of 9.3 years and 61 patients (62%) were male. Overall, patients demonstrated worse UE Function as well as greater Anxiety and Depression in comparison to the population normals on PROMIS assessment. Patients also demonstrated worse patient and parent reported PODCI UE, Sports and Physical Functioning, Pain/Comfort and Global Functioning scores compared with population norms but demonstrated better than average happiness scores. Patients with multiple osteochondromas demonstrated greater PROMIS pain interference and more disability in PODCI Sports and Physical Functioning, Pain/Comfort and Global Functioning compared with those with solitary osteochondromas. CONCLUSION: Patients with UE osteochondromas have worse overall function in comparison to population norms, exceeding established minimally clinically important difference values. In addition, patients with multiple osteochondromas reported more pain and poorer physical function than those with solitary osteochondromas. Physicians should be alert to the physical and psychosocial burden of this disease. LEVEL OF EVIDENCE: Level II-prognostic.


Asunto(s)
Neoplasias Óseas , Exostosis Múltiple Hereditaria , Osteocondroma , Ansiedad/epidemiología , Neoplasias Óseas/fisiopatología , Neoplasias Óseas/psicología , Niño , Depresión/epidemiología , Exostosis Múltiple Hereditaria/fisiopatología , Exostosis Múltiple Hereditaria/psicología , Femenino , Humanos , Masculino , Osteocondroma/fisiopatología , Osteocondroma/psicología , Dolor/epidemiología , Medición de Resultados Informados por el Paciente , Rendimiento Físico Funcional , Sistema de Registros , Extremidad Superior/fisiopatología
2.
Vet Comp Oncol ; 20(4): 817-824, 2022 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-35608271

RESUMEN

Signal transducer and activator of transcription 3 (STAT3) dysregulation has been characterized in canine OS, with previous data suggesting that constitutive STAT3 activation contributes to survival and proliferation in OS cell lines in vitro. Recently, the contribution of STAT3 to tumour metabolism has been described across several tumour histologies, and understanding the metabolic implications of STAT3 loss may elucidate novel therapeutic approaches with synergistic activity. The objective of this work was to characterize metabolic benchmarks associated with STAT3 loss in canine OS. STAT3 expression and activation was evaluated using western blotting in canine OS cell lines OSCA8 and Abrams. STAT3 was deleted from these OS cell lines using CRISPR-Cas9, and the effects on proliferation, invasion and metabolism (respirometry, intracellular lactate) were determined. Loss of STAT3 was associated with decreased basal and compensatory glycolysis in canine OS cell lines, without modulation of cellular proliferation. Loss of STAT3 also resulted in diminished invasive capacity in vitro. Interestingly, the absence of STAT3 did not impact sensitivity to doxorubicin in vitro. Our data demonstrate that loss of STAT3 modulates features of aerobic glycolysis in canine OS impacting capacities for cellular invasions, suggesting a role for this transcription factor in metastasis.


Asunto(s)
Neoplasias Óseas , Enfermedades de los Perros , Osteosarcoma , Animales , Perros , Apoptosis , Neoplasias Óseas/fisiopatología , Neoplasias Óseas/veterinaria , Línea Celular Tumoral , Proliferación Celular , Enfermedades de los Perros/fisiopatología , Osteosarcoma/fisiopatología , Osteosarcoma/veterinaria , Factor de Transcripción STAT3/genética , Factor de Transcripción STAT3/metabolismo , Eliminación de Gen
3.
Int J Mol Sci ; 23(4)2022 Feb 21.
Artículo en Inglés | MEDLINE | ID: mdl-35216464

RESUMEN

Micro ribonucleic acids (miRNAs) are small endogenous noncoding RNAs molecules that regulate gene expression post-transcriptionally. A single miRNA is able to target hundreds of specific messenger RNA (mRNAs) by binding to the 3'-untranslated regions. miRNAs regulate different biological processes such as cell proliferation, differentiation and apoptosis. Altered miRNA expression is certainly related to the development of the most common human diseases, including tumors. Osteosarcoma (OS), Ewing's Sarcoma (ES), and Chondrosarcoma (CS) are the most common primary bone tumors which affect mainly children and adolescents. A significant dysregulation of miRNA expression, in particular of mir-34, mir-21, mir-106, mir-143, and miR-100, has been revealed in OS, ES and CS. In this context, miRNAs can act as either tumor suppressor genes or oncogenes, contributing to the initiation and progression of bone tumors. The in-depth study of these small molecules can thus help to better understand their biological functions in bone tumors. Therefore, this review aims to examine the potential role of miRNAs in bone tumors, especially OS, ES and CS, and to suggest their possible use as potential therapeutic targets for the treatment of bone tumors and as biomarkers for early diagnosis.


Asunto(s)
Neoplasias Óseas/metabolismo , MicroARNs/metabolismo , Neoplasias Óseas/genética , Neoplasias Óseas/fisiopatología , Regulación Neoplásica de la Expresión Génica , Humanos
4.
PLoS One ; 17(1): e0262863, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35073361

RESUMEN

Osteosarcoma represents one of the most common bone tumours in dogs. It commonly occurs in the proximal humerus, the most affected anatomic site. Until recently, amputation or limb-sparing surgery leading to an arthrodesis coupled with chemotherapy were the only available treatments, but they often lead to complications, reduced mobility and highly impact dog's quality of life. Prototypes of both articulated and monobloc (no mobility) patient-specific endoprostheses have been designed to spare the limb afflicted with osteosarcoma of the proximal humerus. This study focuses on the biomechanical effects of endoprostheses and shoulder muscle kinematics. For each of the endoprosthesis designs, a minimal number of muscles needed to ensure stability and a certain degree of joint movement during walking is sought. A quasi-static study based on an optimization method, the minimization of the sum of maximal muscle stresses, was carried out to assess the contribution of each muscle to the shoulder function. The identification of the most important muscles and their impact on the kinematics of the prosthetic joint lead to an improvement of the endoprosthesis design relevance and implantation feasibility.


Asunto(s)
Neoplasias Óseas , Enfermedades de los Perros , Húmero , Locomoción , Músculo Esquelético , Osteosarcoma , Prótesis e Implantes , Escápula , Articulación del Hombro , Animales , Fenómenos Biomecánicos , Neoplasias Óseas/fisiopatología , Neoplasias Óseas/cirugía , Enfermedades de los Perros/fisiopatología , Enfermedades de los Perros/cirugía , Perros , Húmero/fisiopatología , Húmero/cirugía , Masculino , Músculo Esquelético/fisiopatología , Músculo Esquelético/cirugía , Osteosarcoma/fisiopatología , Osteosarcoma/cirugía , Diseño de Prótesis , Escápula/fisiopatología , Escápula/cirugía , Articulación del Hombro/fisiopatología , Articulación del Hombro/cirugía
5.
Nutrients ; 14(2)2022 Jan 17.
Artículo en Inglés | MEDLINE | ID: mdl-35057564

RESUMEN

BACKGROUND: We evaluated nutritional and sarcopenia status and their clinical impact in pediatric patients affected by bone and soft tissue sarcomas. METHODS: Body mass index (BMI), prognostic nutritional index (PNI), and total psoas muscle area (tPMA) at diagnosis and after 12 months were analyzed. tPMA was measured from single cross-sectional computed tomography (CT) images at L4-L5. Age-specific and sex-specific tPMA Z-scores were retrieved from an online calculator. RESULTS: A total of 21 patients were identified between February 2013 and December 2018. Twelve patients (57.1%) experienced sarcopenia at diagnosis, although not statistically associated with overall survival (OS) (p = 0.09). BMI Z-score, PNI, and tPMA Z-score significantly decreased between diagnosis and after 12 months of treatment (p < 0.05). Univariate analysis showed significant associations between poor OS and the presence of metastasis (p = 0.008), the absence of surgery (p = 0.005), PNI decrease (p = 0.027), and the reduction in tPMA > 25% (p = 0.042) over the 12 months. CONCLUSIONS: Sarcopenia affects more than half of the patients at diagnosis. Decreased PNI during 12 months of treatment has significant predictive value for OS. The role of tPMA derived from CT scan among pediatric patients with sarcoma should be investigated in further prospective and larger studies.


Asunto(s)
Neoplasias Óseas/fisiopatología , Desnutrición/complicaciones , Evaluación Nutricional , Proyectos Piloto , Sarcoma/fisiopatología , Sarcopenia/epidemiología , Adolescente , Composición Corporal , Índice de Masa Corporal , Neoplasias Óseas/terapia , Niño , Femenino , Humanos , Infecciones/epidemiología , Masculino , Estado Nutricional , Pronóstico , Estudios Retrospectivos , Rabdomiosarcoma/fisiopatología , Rabdomiosarcoma/terapia , Sarcoma/terapia , Sarcoma de Ewing/fisiopatología , Sarcoma de Ewing/terapia , Tasa de Supervivencia
6.
Lipids Health Dis ; 21(1): 5, 2022 Jan 07.
Artículo en Inglés | MEDLINE | ID: mdl-34996476

RESUMEN

Recent advances in society have resulted in the emergence of both hyperlipidemia and obesity as life-threatening conditions in people with implications for various types of diseases, such as cardiovascular diseases and cancer. This is further complicated by a global rise in the aging population, especially menopausal women, who mostly suffer from overweight and bone loss simultaneously. Interestingly, clinical observations in these women suggest that osteoarthritis may be linked to a higher body mass index (BMI), which has led many to believe that there may be some degree of bone dysfunction associated with conditions such as obesity. It is also common practice in many outpatient settings to encourage patients to control their BMI and lose weight in an attempt to mitigate mechanical stress and thus reduce bone pain and joint dysfunction. Together, studies show that bone is not only a mechanical organ but also a critical component of metabolism, and various endocrine functions, such as calcium metabolism. Numerous studies have demonstrated a relationship between metabolic dysfunction in bone and abnormal lipid metabolism. Previous studies have also regarded obesity as a metabolic disorder. However, the relationship between lipid metabolism and bone metabolism has not been fully elucidated. In this narrative review, the data describing the close relationship between bone and lipid metabolism was summarized and the impact on both the normal physiology and pathophysiology of these tissues was discussed at both the molecular and cellular levels.


Asunto(s)
Huesos/metabolismo , Metabolismo de los Lípidos , Animales , Enfermedades Óseas/metabolismo , Enfermedades Óseas/fisiopatología , Neoplasias Óseas/metabolismo , Neoplasias Óseas/fisiopatología , Huesos/fisiología , Huesos/fisiopatología , Microambiente Celular/fisiología , Colesterol/metabolismo , Colesterol/fisiología , Humanos , Metabolismo de los Lípidos/fisiología , Osteoporosis/metabolismo
7.
Chem Biol Interact ; 351: 109759, 2022 Jan 05.
Artículo en Inglés | MEDLINE | ID: mdl-34826399

RESUMEN

Hypoxia/oxygen-sensing signally is closely associated with many tumor progressions, including osteosarcoma (OS). Previous research principally focused on the function of hypoxia-inducible factor (HIF)-1α and HIF-2α as the major hypoxia-associated transcription factors in OS, however, the role of HIF-3α has not been investigated. Our study found that HIF-3α was upregulated in OS tissues and cell lines. HIF-3α overexpression facilitated cell proliferation and invasion, and inhibited apoptosis, whereas HIF-3α knockdown showed the opposite results. Chromatin immunoprecipitation analysis revealed that lysine demethylase 3A (KDM3A) expression was transcriptionally activated by HIF-3α under hypoxia, and KDM3A occupied the SRY-box transcription factor 9 (SOX9) gene promoter region through H3 lysine 9 dimethylation (H3K9me2). Additionally, rescue results revealed that KDM3A or SOX9 overexpression reversed the effects of HIF-3α silence on cell functions. The Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) pathway inhibitor cucurbitacin I suppressed the promotive effects of HIF-3α overexpression on cell proliferation, invasion and TAK2/STAT3 pathway. Finally, OS cell line MG-63 transfected with HIF-3α short hairpin RNA (HIF-3α shRNA) were subcutaneously injected into nude mice, and the results found that HIF-3α knockdown significantly inhibited the xenograft tumor growth of OS in vivo. In conclusion, this study reveals that HIF-3α promotes OS progression in vitro and in vivo by activating KDM3A-mediated SOX9 promoter demethylation, which may provide a potential therapeutic mechanism for OS.


Asunto(s)
Proteínas Reguladoras de la Apoptosis/metabolismo , Neoplasias Óseas/fisiopatología , Histona Demetilasas con Dominio de Jumonji/metabolismo , Osteosarcoma/fisiopatología , Proteínas Represoras/metabolismo , Factor de Transcripción SOX9/metabolismo , Animales , Apoptosis/fisiología , Proliferación Celular/fisiología , Femenino , Humanos , Masculino , Metilación/efectos de los fármacos , Ratones Endogámicos BALB C , Transducción de Señal/fisiología
8.
Curr Osteoporos Rep ; 19(6): 580-591, 2021 12.
Artículo en Inglés | MEDLINE | ID: mdl-34729693

RESUMEN

PURPOSE OF REVIEW: In this review, we provide an overview of what is currently known about the impacts of mechanical stimuli on metastatic tumor-induced bone disease (TIBD). Further, we focus on the role of the osteocyte, the skeleton's primary mechanosensory cell, which is central to the skeleton's mechanoresponse, sensing and integrating local mechanical stimuli, and then controlling the downstream remodeling balance as appropriate. RECENT FINDINGS: Exercise and controlled mechanical loading have anabolic effects on bone tissue in models of bone metastasis. They also have anti-tumorigenic properties, in part due to offsetting the vicious cycle of osteolytic bone loss as well as regulating inflammatory signals. The impacts of metastatic cancer on the mechanosensory function of osteocytes remains unclear. Increased mechanical stimuli are a potential method for mitigating TIBD.


Asunto(s)
Biofisica , Neoplasias Óseas/fisiopatología , Neoplasias Óseas/secundario , Remodelación Ósea , Osteocitos/fisiología , Animales , Fenómenos Biomecánicos , Humanos , Ratones , Estrés Mecánico
9.
Cells ; 10(11)2021 10 25.
Artículo en Inglés | MEDLINE | ID: mdl-34831100

RESUMEN

Bone metastasis (BM) is the most common malignant bone tumor and a significant cause of morbidity and mortality for patients with cancer. Compared to other metastatic organs, bone has unique characteristics in terms of the tumor microenvironment (TME). Precise assessments of the TME in BM could be an important step for developing an optimized management plan for patient care. Imaging approaches for BM have several advantages, such as biopsy not being required, multiple site evaluation, and serial assessment in the same sites. Owing to the developments of new imaging tracers or imaging modalities, bone TME could be visualized using multimodal imaging techniques. In this review, we describe the BM pathophysiology, diagnostic principles of major imaging modalities, and clinically available imaging modalities to visualize the TME in BM. We also discuss how the interactions between various factors affecting the TME could be visualized using multimodal imaging techniques.


Asunto(s)
Neoplasias Óseas/diagnóstico por imagen , Neoplasias Óseas/secundario , Imagen Multimodal , Microambiente Tumoral , Animales , Neoplasias Óseas/patología , Neoplasias Óseas/fisiopatología , Diferenciación Celular , Humanos
10.
Indian J Pathol Microbiol ; 64(4): 717-724, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34673591

RESUMEN

OBJECTIVE: To analyze the clinicopathological features of metastatic bone tumors over a period of two decades and identify the primary site of malignancy in metastasis of unknown origin. MATERIALS AND METHODS: A total number of 365 cases were included in the study. The clinical features and location of the tumors were noted. The histopathological features of all the cases were studied. Immunohistochemistry (IHC) was done either to categorize or confirm the primary diagnosis using organ specific/organ restricted markers. RESULTS: A total 712 bony sites were involved by metastasis in 365 patients, of which spine was the most commonly affected. Metastasis was the initial presentation in 69.5% patients. The primary site was known in 220 patients and almost half of them were detected after the diagnosis of metastasis. IHC was used as adjunct to suggest the possible origin in cases with unknown primary in 27.4%. Among the metastatic carcinoma, adenocarcinoma was the most common histological subtype with thyroid being the most frequent primary site of origin followed by lung and breast. CONCLUSION: More than two-third of cases in surgical pathology practice present as initial manifestations. Detection rate of primary depends on extent of metastatic work-up and IHC with organ specific/organ restricted markers to facilitate treatment with bone targeting agents.


Asunto(s)
Neoplasias Óseas/diagnóstico , Neoplasias Óseas/fisiopatología , Carcinoma/diagnóstico , Carcinoma/fisiopatología , Inmunohistoquímica/métodos , Metástasis de la Neoplasia/diagnóstico , Metástasis de la Neoplasia/fisiopatología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Adulto Joven
11.
Eur J Histochem ; 65(3)2021 Sep 03.
Artículo en Inglés | MEDLINE | ID: mdl-34474553

RESUMEN

Osteosarcoma (OS) is the most prevalent malignant bone tumor in children and young adults. There is an urgent need for a novel biomarker related to the prognosis of OS. We performed a meta-analysis incorporating six independent datasets and performed a survival analysis with one independent dataset GSE21257 in the GEO database for gene screening. The results revealed that one potential biomarker related to OS survival, POGZ was the most significantly upregulated gene. We also verified that the POGZ was overexpressed in clinical samples. The survival analysis revealed that POGZ is associated with a poor prognosis in OS. Moreover, flow cytometry analysis of isolated OS cells demonstrated that OS cells were arrested in the G1 phase after POGZ knockdown. The RNA-seq results indicated that POGZ was co-expressed with CCNE1 and CCNB1. Pathway analysis showed that genes associated with high expression levels of POGZ were related to the cell cycle pathway. A cell model was constructed to detect the effects of POGZ. After POGZ knockdown, OS cell proliferation, invasion and migration were all decreased. Therefore, POGZ is an important gene for evaluating the prognosis of OS patients and is a potential therapeutic target.


Asunto(s)
Biomarcadores de Tumor/metabolismo , Neoplasias Óseas/diagnóstico , Osteosarcoma/diagnóstico , Transposasas/metabolismo , Adulto , Biomarcadores de Tumor/genética , Neoplasias Óseas/metabolismo , Neoplasias Óseas/patología , Neoplasias Óseas/fisiopatología , Ciclo Celular/fisiología , Línea Celular Tumoral , Movimiento Celular/fisiología , Proliferación Celular/fisiología , Femenino , Regulación Neoplásica de la Expresión Génica/fisiología , Técnicas de Silenciamiento del Gen , Humanos , Masculino , Invasividad Neoplásica/fisiopatología , Osteosarcoma/metabolismo , Osteosarcoma/patología , Osteosarcoma/fisiopatología , Pronóstico , Transposasas/genética , Adulto Joven
12.
Indian J Cancer ; 58(3): 326-335, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34558441

RESUMEN

Primary bone tumors, including sarcomas, are rare tumors and require a multidisciplinary approach, including inputs from a radiologist, pathologist, medical oncologist, and surgical and radiation oncologist, for optimal management. Over the years, there has been a paradigm shift toward the treatment of bone sarcomas, from radical resections to conservative surgical procedures, to achieve improved clinical and functional outcomes. This has led to receiving and processing various types of specimens in orthopedic oncopathology. Grossing and reporting of bone tumors require expertise. This review focuses upon the types of biopsies, grossing techniques of various specimens in orthopedic oncology and reporting, with rationale and recommendations from pathologists, actively involved in reporting and pursuing a special interest in bone tumors, based on current evidence. Furthermore, there is a section on some of the updates in the diagnosis of bone tumors, based on the recent fifth edition of the World Health Organization classification of tumors of soft tissues and bone.


Asunto(s)
Neoplasias Óseas/fisiopatología , Oncología Quirúrgica/métodos , Humanos
13.
Taiwan J Obstet Gynecol ; 60(4): 787-790, 2021 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-34247828

RESUMEN

OBJECTIVE: We present a case of successful pregnancy in a patient who underwent limb-sparing hemipelvectomy combined with multi-agent chemotherapy and radiotherapy for Ewing sarcoma. CASE REPORT: A 17-year-old girl was diagnosed with Ewing sarcoma of the left pelvis at the age of 17 and received limb-sparing hemipelvectomy combined with multi-agent chemotherapy and radiotherapy. The patient received oral contraceptives as hormone replacement therapy after completion of treatment. A normal menstruation cycle restored after the withdrawal of oral contraceptives. The patient spontaneously conceived at the age of 25. The patient complained of difficulty walking due to pelvic distortion during pregnancy and delivered a healthy neonate at term by cesarean section. CONCLUSION: Successful pregnancy and delivery can be achieved after limb-sparing hemipelvectomy combined with chemotherapy and radiotherapy for Ewing sarcoma. Our report provides important information on perinatal management, given the low incidence of pregnancy following treatment of Ewing sarcoma in the pelvis.


Asunto(s)
Neoplasias Óseas/fisiopatología , Fertilización , Hemipelvectomía , Parto , Sarcoma de Ewing/fisiopatología , Adolescente , Adulto , Neoplasias Óseas/cirugía , Quimioradioterapia , Terapia Combinada , Anticonceptivos Hormonales Orales , Femenino , Humanos , Nacimiento Vivo , Huesos Pélvicos , Periodo Posoperatorio , Embarazo , Sarcoma de Ewing/cirugía
14.
Jt Dis Relat Surg ; 32(2): 514-520, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34145831

RESUMEN

Osteochondromas are neoplasm that belong to the family of cartilaginous histogenesis tumors and represent 90% of all forms of exostoses. As most osteochondromas are asymptomatic, underdiagnosis is frequent. Symptomatic forms usually manifest before the age of 20 years, and the most common symptoms are pain and the detection of a bony mass. Herein, we report four cases of spontaneous regression of solitary osteochondromas in the light of literature. We consider that orthopedic surgeons should take into account the possibility of spontaneous regression of these tumors, before recommending surgery. Symptoms are usually mild and we recommend following these patients with X-ray and physical examination annually.


Asunto(s)
Neoplasias Óseas/fisiopatología , Exostosis/fisiopatología , Regresión Neoplásica Espontánea/fisiopatología , Osteocondroma/fisiopatología , Neoplasias Óseas/diagnóstico por imagen , Niño , Preescolar , Exostosis/diagnóstico por imagen , Humanos , Masculino , Osteocondroma/diagnóstico por imagen , España
15.
Hum Exp Toxicol ; 40(11): 1985-1997, 2021 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-34002651

RESUMEN

MG132 is a potent, reversible, and cell-permeable 20S proteasome inhibitor and it is derived from a Chinese medicinal plant. The purpose of this study is to investigate the anticancer effects of MG132 against human osteosarcoma U2OS cells. We first performed MTT and colony formation assays to investigate the anti-proliferative effects of MG132. The results demonstrated that MG132 suppressed the proliferation of U2OS cells. Furthermore, we found that treatment with MG132 increased apoptosis and induced DNA damage in U2OS cells. Additionally, zymography, wound healing, and invasion assays showed that MG132 suppressed the enzymatic activity of matrix metalloproteinases, cell migration, and invasion, respectively of U2OS cells. Furthermore, western blotting assay was performed to investigate the apoptotic signaling pathways in MG132-treated U2OS cells. Our results showed that MG132 downregulated the expression of antiapoptotic proteins, including CDK2, CDK4, Bcl-xL, and Bcl-2, whereas it upregulated the expression of proapoptotic proteins, including p21, p27, p53, p-p53 (ser15, ser20, and ser46), cleaved forms of caspase-3, caspase-7, caspase-9, and PARP, and FOXO3 in U2OS cells. These results demonstrated that MG132 activated apoptotic signaling pathways in U2OS cells. Interestingly, MG132 downregulated the phosphorylation of Akt and Erk. Taken together, our results suggest that MG132 has anticancer effects in U2OS cells. Therefore, MG132 may be a potential therapeutic agent for the treatment of osteosarcoma.


Asunto(s)
Antineoplásicos/uso terapéutico , Apoptosis/efectos de los fármacos , Neoplasias Óseas/tratamiento farmacológico , Línea Celular Tumoral/efectos de los fármacos , Daño del ADN/efectos de los fármacos , Osteosarcoma/tratamiento farmacológico , Inhibidores de Proteasoma/uso terapéutico , Neoplasias Óseas/fisiopatología , Humanos , Medicina Tradicional China , Osteosarcoma/fisiopatología
16.
J Orthop Surg Res ; 16(1): 286, 2021 Apr 29.
Artículo en Inglés | MEDLINE | ID: mdl-33926481

RESUMEN

BACKGROUND: This study is to describe the design and surgical techniques of three- dimensional-printed porous implants for proximal giant cell tumors of bone and evaluate the short-term clinical outcomes. METHODS: From December 2016 to April 2020, 8 patients with giant cell tumor of bone in the proximal tibia underwent intralesional curettage of the tumor and reconstruction with bone grafting and three-dimensional-printed porous implant. Detailed anatomy data were measured, including the size of lesion and thickness of the subchondral bone. Prostheses were custom-made for each patient by our team. All patients were evaluated regularly and short-term clinical outcomes were recorded. RESULTS: The mean follow-up period was 26 months. According to the different defect sizes, the mean size of the plate and mean length of strut were 35 × 35 mm and 20 mm, respectively. The mean affected subchondral bone percentage was 31.5%. The average preoperative and postoperative thickness of the subchondral bone was 2.1 mm and 11.1 mm, respectively. There was no wound infection, skin necrosis, peroneal nerve injury, or other surgical related complications. No degeneration of the knee joint was found. Osseointegration was observed in all patients. The MSTS improved from an average of 12 preoperatively to 28 postoperatively. CONCLUSION: The application of three-dimensional-printed printed porous prosthesis combined autograft could supply enough mechanical support and enhance bone ingrowth. The design and operation management lead to satisfactory subchondral bone reconstruction.


Asunto(s)
Autoinjertos , Neoplasias Óseas/cirugía , Trasplante Óseo/métodos , Legrado/métodos , Tumor Óseo de Células Gigantes/cirugía , Procedimientos Ortopédicos/métodos , Procedimientos de Cirugía Plástica/métodos , Porosidad , Impresión Tridimensional , Diseño de Prótesis/métodos , Tibia/cirugía , Adulto , Neoplasias Óseas/patología , Neoplasias Óseas/fisiopatología , Femenino , Estudios de Seguimiento , Tumor Óseo de Células Gigantes/patología , Tumor Óseo de Células Gigantes/fisiopatología , Humanos , Masculino , Persona de Mediana Edad , Tibia/patología , Tibia/fisiopatología , Factores de Tiempo , Resultado del Tratamiento
17.
Int J Mol Sci ; 22(7)2021 Mar 31.
Artículo en Inglés | MEDLINE | ID: mdl-33807419

RESUMEN

Osteosarcoma (OSA) represents the most common bone tumor in dogs. The malignancy is highly aggressive, and most of the dogs die due to metastasis, especially to the lungs. The metastatic process is complex and consists of several main steps. Assessment of the molecular mechanisms of metastasis requires in vitro and especially in vivo studies for a full evaluation of the process. The molecular and biological resemblance of canine OSA to its human counterpart enables the utilization of dogs as a spontaneous model of this disease in humans. The aim of the present review article is to summarize the knowledge of genes and proteins, including p63, signal transducer and activator of transcription 3 (STAT3), Snail2, ezrin, phosphorylated ezrin-radixin-moesin (p-ERM), hepatocyte growth factor-scatter factor (HGF-SF), epidermal growth factor receptor (EGFR), miR-9, and miR-34a, that are proven, by in vitro and/or in vivo studies, to be potentially involved in the metastatic cascade of canine OSA. The determination of molecular targets of metastatic disease may enhance the development of new therapeutic strategies.


Asunto(s)
Metástasis de la Neoplasia/fisiopatología , Osteosarcoma/metabolismo , Animales , Neoplasias Óseas/genética , Neoplasias Óseas/metabolismo , Neoplasias Óseas/fisiopatología , Línea Celular Tumoral , Proteínas del Citoesqueleto/metabolismo , Modelos Animales de Enfermedad , Perros , Receptores ErbB/metabolismo , Regulación Neoplásica de la Expresión Génica/genética , Factor de Crecimiento de Hepatocito/metabolismo , MicroARNs , Metástasis de la Neoplasia/genética , Osteosarcoma/veterinaria , Fosforilación , Factor de Transcripción STAT3/metabolismo , Factores de Transcripción de la Familia Snail/metabolismo , Proteínas Supresoras de Tumor/metabolismo
18.
J Vasc Interv Radiol ; 32(4): 504-509, 2021 04.
Artículo en Inglés | MEDLINE | ID: mdl-33612370

RESUMEN

PURPOSE: To evaluate safety and long-term efficacy of radiofrequency (RF) ablation in treatment of chondroblastoma. MATERIALS AND METHODS: This retrospective analysis comprised 27 consecutive patients with histopathologically proven chondroblastoma treated by RF ablation. The tumors were located in the proximal humerus (n = 6), proximal tibia (n = 8), proximal femur (n = 6), distal femur (n = 5), acromion process (n = 1), and lunate (n = 1). In 19 patients (70.3%), the tumor was in the weight-bearing area of the bone. Clinical response was assessed by comparing pain scores and functional assessment by Musculoskeletal Tumor Society (MSTS) score before and after ablation. Patients were followed for a minimum of 1 year to rule out complications and recurrence. RESULTS: Technical success rate was 100%. Mean pain score before the procedure was 7.34 (range, 7-9); all patients experienced a reduction in pain, with 25 (92.6%) patients reporting complete pain relief at 6 weeks. Mean MSTS score before the procedure was 15.4, whereas mean MSTS score at 6 weeks after the procedure was 28.6, suggesting significant functional improvement (P < .0001). Two patients developed osteonecrosis and collapse of the treated bone. There were no recurrences. CONCLUSIONS: Percutaneous RF ablation is a safe and effective option for treating chondroblastoma of the appendicular skeleton.


Asunto(s)
Neoplasias Óseas/cirugía , Condroblastoma/cirugía , Ablación por Radiofrecuencia , Adolescente , Adulto , Neoplasias Óseas/diagnóstico por imagen , Neoplasias Óseas/fisiopatología , Niño , Condroblastoma/diagnóstico por imagen , Condroblastoma/patología , Estudios de Factibilidad , Femenino , Humanos , Imagen por Resonancia Magnética , Masculino , Complicaciones Posoperatorias/etiología , Ablación por Radiofrecuencia/efectos adversos , Radiografía Intervencional , Estudios Retrospectivos , Centros de Atención Terciaria , Factores de Tiempo , Tomografía Computarizada por Rayos X , Resultado del Tratamiento , Adulto Joven
19.
Biotechnol Bioeng ; 118(5): 1779-1792, 2021 05.
Artículo en Inglés | MEDLINE | ID: mdl-33491767

RESUMEN

Incurable breast cancer bone metastasis causes widespread bone loss, resulting in fragility, pain, increased fracture risk, and ultimately increased patient mortality. Increased mechanical signals in the skeleton are anabolic and protect against bone loss, and they may also do so during osteolytic bone metastasis. Skeletal mechanical signals include interdependent tissue deformations and interstitial fluid flow, but how metastatic tumor cells respond to each of these individual signals remains underinvestigated, a barrier to translation to the clinic. To delineate their respective roles, we report computed estimates of the internal mechanical field of a bone mimetic scaffold undergoing combinations of high and low compression and perfusion using multiphysics simulations. Simulations were conducted in advance of multimodal loading bioreactor experiments with bone metastatic breast cancer cells to ensure that mechanical stimuli occurring internally were physiological and anabolic. Our results show that mechanical stimuli throughout the scaffold were within the anabolic range of bone cells in all loading configurations, were homogenously distributed throughout, and that combined high magnitude compression and perfusion synergized to produce the largest wall shear stresses within the scaffold. These simulations, when combined with experiments, will shed light on how increased mechanical loading in the skeleton may confer anti-tumorigenic effects during metastasis.


Asunto(s)
Fenómenos Biomecánicos/fisiología , Reactores Biológicos , Neoplasias Óseas , Neoplasias de la Mama , Ingeniería de Tejidos/métodos , Microambiente Tumoral/fisiología , Neoplasias Óseas/fisiopatología , Neoplasias Óseas/secundario , Neoplasias de la Mama/patología , Neoplasias de la Mama/fisiopatología , Femenino , Humanos , Estrés Mecánico
20.
Clin Orthop Relat Res ; 479(6): 1285-1293, 2021 06 01.
Artículo en Inglés | MEDLINE | ID: mdl-33399403

RESUMEN

BACKGROUND: Ten years ago, we reported the results of a procedure in which we translocated the ipsilateral ulna as a vascularized autograft to reconstruct defects of the distal radius after tumor resection, with excellent functional results. At that time, wrist arthrodesis was achieved by aligning the translocated ulna with the scapholunate area of the carpus and usually the third metacarpal. This resulted in wrist narrowing. We then wondered if aligning the translocated ulna with the scaphoid and the second metacarpal would result in ulnar deviation and thereby improve grip strength. We believed lateralization would reduce the wrist narrowing that occurs with fusion to the third metacarpal and would make the cosmesis more acceptable. We also modified the incision to dororadial to make the scar less visible and thus improve the cosmesis. QUESTIONS/PURPOSES: (1) Is there an objective improvement in grip strength and functional scores (Musculoskeletal Tumor Society [MSTS] and Mayo wrist) when the translocated ulna is lateralized and the wrist is fused with the translocated ulna and aligned with the second metacarpal versus when the translocated ulna is aligned with the third metacarpal? (2) Did lateralization caused by the wrist fusion aligned with the second metacarpal minimize wrist narrowing as measured by the circumference compared with the fusion aligned with the third metacarpal? METHODS: From 2010 and 2018, we treated 40 patients with distal radius tumors at our institution, 30 of whom had a distal radius enbloc resection. Twenty-eight patients had an ipsilateral ulna translocation and wrist arthrodesis in which the radius and translocated ulna were aligned with either the second (n = 15) or the third (n = 13) metacarpals. Two patients in the second metacarpal group and three patients in the third metacarpal group were lost to follow-up before 24 months after surgery and were excluded. A retrospective analysis of 23 patients (20 with giant cell tumors and three with malignant bone tumors) included a review of radiographs and institutional tumor database for surgical and follow-up records to study oncologic (local disease recurrence), reconstruction (union of osteotomy junctions, implant breakage or graft fracture, and wrist circumference), and functional outcomes (MSTS and Mayo wrist scores and objective grip strength assessment compared with the contralateral side). The results were compared for each study group (second metacarpal versus third metacarpal). There was no difference in the incidence of local recurrence or the time to union between the two groups. There were no implant breakages or graft fractures noted in either group. RESULTS: Patients in the second metacarpal group lost less grip strength compared with the unoperated side in the third metacarpal group (median 12% [range -30% to 35%] versus median 28% [15% to 42%], difference of medians 16%; p = 0.006). There were no between-group differences in terms of MSTS (median 30 [24 to 30] versus median 26.5 [22 to 30], difference of medians 3.5; p = 0.21) or Mayo wrist scores (median 83 [65 to 100] versus median 72 [50 to 90], difference of medians 11; p = 0.10). The second metacarpal group also had less wrist narrowing as seen from the median difference in circumference between the operated and unoperated wrists (median narrowing 10 mm [3 to 35 mm] in the second metacarpal group versus median 30 mm [15 to 35 mm] in the third metacarpal group, difference of medians 20 mm; p = 0.04). CONCLUSION: Wrist arthrodesis after ulna translocation with alignment of the translocated ulna and the second metacarpal provides a functional position with ulnar deviation that offers some improvement in grip strength but no improvement in the MSTS or Mayo scores. Radialization/lateralization of the translocated ulna achieved from the alignment with the second metacarpal decreases the reduction in the wrist circumference and therefore reduces wrist narrowing. LEVEL OF EVIDENCE: Level III, therapeutic study.


Asunto(s)
Artrodesis/métodos , Neoplasias Óseas/cirugía , Tumor Óseo de Células Gigantes/cirugía , Osteotomía/métodos , Cúbito/trasplante , Muñeca/cirugía , Neoplasias Óseas/fisiopatología , Trasplante Óseo , Femenino , Tumor Óseo de Células Gigantes/fisiopatología , Fuerza de la Mano , Humanos , Masculino , Radio (Anatomía)/cirugía , Rango del Movimiento Articular , Estudios Retrospectivos , Resultado del Tratamiento , Muñeca/fisiopatología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...